Skip to main content
Top
Published in: Journal of Bone and Mineral Metabolism 4/2019

01-07-2019 | Original Article

Quantitation and distribution of metallic elements in sequestra of medication-related osteonecrosis of jaw (MRONJ) using inductively coupled plasma atomic emission spectroscopy and synchrotron radiation X-ray fluorescence analysis

Authors: Ruri Komiya, Takahiro Wada, Fumihiko Tsushima, Kei Sakamoto, Tohru Ikeda, Akira Yamaguchi, Hiroyuki Harada, Motohiro Uo

Published in: Journal of Bone and Mineral Metabolism | Issue 4/2019

Login to get access

Abstract

Medication-related osteonecrosis of the jaw (MRONJ) is a serious adverse effect of antiresorptive agents like bisphosphonates. Abnormal concentrations of various trace metallic elements contained in bone minerals have been associated with MRONJ. In this study, we focused on trace metallic elements contained in the MRONJ sequestrum; their content and distribution were compared to those in osteomyelitis and non-inflammatory bones using inductively coupled plasma atomic emission spectroscopy (ICP-AES) and synchrotron radiation X-ray fluorescence analysis (SR-XRF). On ICP-AES analyses, various trace elements (Co, Cr, Cu, Fe, K, Mg, Ni, Sb, Ti, V, Pb) were significantly more in MRONJ sequestra than non-inflammatory bones. The Cu content was significantly higher in MRONJ sequestra than osteomyelitis and non-inflammatory bones. The Cu content in MRONJ sequestra was high even after decalcification. Additionally, Cu was distributed along the trabecular structures in decalcified MRONJ specimens, as observed using SR-XRF analysis. Therefore, this study was indicative of the characteristic behavior of Cu in MRONJ.
Appendix
Available only for authorised users
Literature
1.
go back to reference Marx RE (2003) Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaw: a growing epidemic. J Oral Maxillofac Surg 61:1115–1117CrossRefPubMed Marx RE (2003) Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaw: a growing epidemic. J Oral Maxillofac Surg 61:1115–1117CrossRefPubMed
2.
go back to reference Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, O’Ryan F (2014) American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw—2014 update. J Oral Maxillofac Surg 72:1938–1956CrossRefPubMed Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, O’Ryan F (2014) American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw—2014 update. J Oral Maxillofac Surg 72:1938–1956CrossRefPubMed
3.
go back to reference Coleman R, Woodward E, Brown J, Cameron D, Bell R, Dodwell D, Keane M, Gil M, Davies C, Burkinshaw R, Houston SJ, Grieve RJ, Barrett-Lee PJ, Thorpe H (2011) Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01–04) for women with stage II/III breast cancer. Breast Cancer Res Treat 127:429–438CrossRefPubMed Coleman R, Woodward E, Brown J, Cameron D, Bell R, Dodwell D, Keane M, Gil M, Davies C, Burkinshaw R, Houston SJ, Grieve RJ, Barrett-Lee PJ, Thorpe H (2011) Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01–04) for women with stage II/III breast cancer. Breast Cancer Res Treat 127:429–438CrossRefPubMed
4.
go back to reference Vahtsevanos K, Kyrgidis A, Verrou E, Katodritou E, Triaridis S, Andreadis CG, Boukovinas I, Koloutsos GE, Teleioudis Z, Kitikidou K, Paraskevopoulos P, Zervas K, Antoniades K (2009) Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J Clin Oncol 27:5356–5362CrossRefPubMed Vahtsevanos K, Kyrgidis A, Verrou E, Katodritou E, Triaridis S, Andreadis CG, Boukovinas I, Koloutsos GE, Teleioudis Z, Kitikidou K, Paraskevopoulos P, Zervas K, Antoniades K (2009) Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J Clin Oncol 27:5356–5362CrossRefPubMed
5.
go back to reference Lo JC, O’Ryan FS, Gordon NP, Yang J, Hui RL, Martin D, Hutchinson M, Lathon PV, Sanchez G, Silver P, Chandra M, McCloskey CA, Staffa JA, Willy M, Selby JV, Go AS (2010) Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. J Oral Maxillofac Surg 68:243–253CrossRefPubMed Lo JC, O’Ryan FS, Gordon NP, Yang J, Hui RL, Martin D, Hutchinson M, Lathon PV, Sanchez G, Silver P, Chandra M, McCloskey CA, Staffa JA, Willy M, Selby JV, Go AS (2010) Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. J Oral Maxillofac Surg 68:243–253CrossRefPubMed
6.
go back to reference Qi WX, Tang LN, He AN, Yao Y, Shen Z (2014) Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials. Int J Clin Oncol 16:403–410CrossRef Qi WX, Tang LN, He AN, Yao Y, Shen Z (2014) Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials. Int J Clin Oncol 16:403–410CrossRef
7.
go back to reference Gaudin E, Seidel L, Bacevic M, Rompen E, Lambert F (2015) Occurrence and risk indicators of medication-related osteonecrosis of the jaw after dental extraction: a systematic review and meta-analysis. J Clin Periodontol 42:922–932CrossRefPubMed Gaudin E, Seidel L, Bacevic M, Rompen E, Lambert F (2015) Occurrence and risk indicators of medication-related osteonecrosis of the jaw after dental extraction: a systematic review and meta-analysis. J Clin Periodontol 42:922–932CrossRefPubMed
8.
go back to reference Kim JW, Kong KA, Kim SJ, Choi SK, Cha IH, Kim MR (2013) Prospective biomarker evaluation in patients with osteonecrosis of the jaw who received bisphosphonates. Bone 57:201–205CrossRefPubMed Kim JW, Kong KA, Kim SJ, Choi SK, Cha IH, Kim MR (2013) Prospective biomarker evaluation in patients with osteonecrosis of the jaw who received bisphosphonates. Bone 57:201–205CrossRefPubMed
9.
go back to reference Marx RE, Cillo JE, Ulloa JJ (2007) Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 65:2397–2410CrossRefPubMed Marx RE, Cillo JE, Ulloa JJ (2007) Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 65:2397–2410CrossRefPubMed
10.
go back to reference Lowe NM, Fraser WD, Jackson MJ (2002) Is there a potential therapeutic value of copper and zinc for osteoporosis? Proc Nutr Soc 61:181–185CrossRefPubMed Lowe NM, Fraser WD, Jackson MJ (2002) Is there a potential therapeutic value of copper and zinc for osteoporosis? Proc Nutr Soc 61:181–185CrossRefPubMed
11.
go back to reference Koçer G, Nazıroğlu M, Çelik Ö, Önal L, Özçelik D, Koçer M, Sönmez TT (2013) Basic fibroblast growth factor attenuates bisphosphonate-induced oxidative injury but decreases zinc and copper levels in oral epithelium of rat. Biol Trace Elem Res 153:251–256CrossRefPubMed Koçer G, Nazıroğlu M, Çelik Ö, Önal L, Özçelik D, Koçer M, Sönmez TT (2013) Basic fibroblast growth factor attenuates bisphosphonate-induced oxidative injury but decreases zinc and copper levels in oral epithelium of rat. Biol Trace Elem Res 153:251–256CrossRefPubMed
12.
go back to reference Sugiyama T, Uo M, Mizoguchi T, Wada T, Omagari D, Komiyama K, Mori Y (2015) Copper accumulation in the sequestrum of medication-related osteonecrosis of the jaw. Bone Rep 3:40–47CrossRefPubMedPubMedCentral Sugiyama T, Uo M, Mizoguchi T, Wada T, Omagari D, Komiyama K, Mori Y (2015) Copper accumulation in the sequestrum of medication-related osteonecrosis of the jaw. Bone Rep 3:40–47CrossRefPubMedPubMedCentral
13.
go back to reference Baslé MF, Mauras Y, Audran M, Clochon P, Rebel A, Allain P (1990) Concentration of bone elements in osteoporosis. J Bone Miner Res 5:41–47CrossRefPubMed Baslé MF, Mauras Y, Audran M, Clochon P, Rebel A, Allain P (1990) Concentration of bone elements in osteoporosis. J Bone Miner Res 5:41–47CrossRefPubMed
14.
go back to reference Chappard D, Bizot P, Mabilleau G, Hubert L (2016) Aluminum and bone: review of new clinical circumstances associated with Al3+ deposition in the calcified matrix of bone. Morphologie 100:95–105CrossRefPubMed Chappard D, Bizot P, Mabilleau G, Hubert L (2016) Aluminum and bone: review of new clinical circumstances associated with Al3+ deposition in the calcified matrix of bone. Morphologie 100:95–105CrossRefPubMed
16.
go back to reference Tisato F, Marzano C, Porchia M, Pellei M, Santini C (2010) Copper in diseases and treatments, and copper-based anticancer strategies. Med Res Rev 30:708–749PubMed Tisato F, Marzano C, Porchia M, Pellei M, Santini C (2010) Copper in diseases and treatments, and copper-based anticancer strategies. Med Res Rev 30:708–749PubMed
17.
18.
go back to reference Marquardt ML, Done SL, Sandrock M, Berdon WE, Feldman KW (2012) Copper deficiency presenting as metabolic bone disease in extremely low birth weight, short-gut infants. Pediatrics 130:e1–e4CrossRef Marquardt ML, Done SL, Sandrock M, Berdon WE, Feldman KW (2012) Copper deficiency presenting as metabolic bone disease in extremely low birth weight, short-gut infants. Pediatrics 130:e1–e4CrossRef
19.
go back to reference Qu X, He Z, Qiao H, Zhai Z, Mao Z, Yu Z, Dai K (2018) Serum copper levels are associated with bone mineral density and total fracture. J Orthop Transl 14:34–44 Qu X, He Z, Qiao H, Zhai Z, Mao Z, Yu Z, Dai K (2018) Serum copper levels are associated with bone mineral density and total fracture. J Orthop Transl 14:34–44
20.
go back to reference Rico H, Roca-Botran C, Hernández ER, Seco C, Paez E, Valencia MJ, Villa LF (2000) The effect of supplemental copper on osteopenia induced by ovariectomy in rats. Menopause 7:413–416CrossRefPubMed Rico H, Roca-Botran C, Hernández ER, Seco C, Paez E, Valencia MJ, Villa LF (2000) The effect of supplemental copper on osteopenia induced by ovariectomy in rats. Menopause 7:413–416CrossRefPubMed
21.
go back to reference Rest JR (1976) The histological effects of copper and zinc on chick embryo skeletal tissues in organ culture. Br J Nutr 36:243–256CrossRefPubMed Rest JR (1976) The histological effects of copper and zinc on chick embryo skeletal tissues in organ culture. Br J Nutr 36:243–256CrossRefPubMed
22.
go back to reference Kaji T, Kawatani R, Takata M, Hoshino T, Miyahara T, Kozuka H, Koizumi F (1988) The effect of cadmium, copper or zinc on formation of embryonic chick bone in tissue culture. Toxicology 50:303–316CrossRefPubMed Kaji T, Kawatani R, Takata M, Hoshino T, Miyahara T, Kozuka H, Koizumi F (1988) The effect of cadmium, copper or zinc on formation of embryonic chick bone in tissue culture. Toxicology 50:303–316CrossRefPubMed
23.
go back to reference Li S, Wang M, Chen X, Li SF, Ling L, Xie HQ (2014) Inhibition of osteogenic differentiation of mesenchymal stem cells by copper supplementation. Cell Prolif 47:81–90CrossRefPubMedPubMedCentral Li S, Wang M, Chen X, Li SF, Ling L, Xie HQ (2014) Inhibition of osteogenic differentiation of mesenchymal stem cells by copper supplementation. Cell Prolif 47:81–90CrossRefPubMedPubMedCentral
24.
go back to reference Massie HR, Aiello VR, Shumway ME, Armstrong T (1990) Calcium, iron, copper, boron, collagen, and density changes in bone with aging in C57BL/6 J male mice. Exp Gerontol 25:469–481CrossRefPubMed Massie HR, Aiello VR, Shumway ME, Armstrong T (1990) Calcium, iron, copper, boron, collagen, and density changes in bone with aging in C57BL/6 J male mice. Exp Gerontol 25:469–481CrossRefPubMed
Metadata
Title
Quantitation and distribution of metallic elements in sequestra of medication-related osteonecrosis of jaw (MRONJ) using inductively coupled plasma atomic emission spectroscopy and synchrotron radiation X-ray fluorescence analysis
Authors
Ruri Komiya
Takahiro Wada
Fumihiko Tsushima
Kei Sakamoto
Tohru Ikeda
Akira Yamaguchi
Hiroyuki Harada
Motohiro Uo
Publication date
01-07-2019
Publisher
Springer Japan
Published in
Journal of Bone and Mineral Metabolism / Issue 4/2019
Print ISSN: 0914-8779
Electronic ISSN: 1435-5604
DOI
https://doi.org/10.1007/s00774-018-0975-3

Other articles of this Issue 4/2019

Journal of Bone and Mineral Metabolism 4/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine